Frontage has successfully filed an Investigational New Drug (IND) on behalf of Zhejiang Hisun Pharmaceutical Co. to initiate an early phase clinical study for HS-25, a cholesterol-lowering compound to treat hypercholesterolemia and nephrotic hyperlipidemia.   As the U.S. regulatory agent for Hisun, Frontage supported the HS-25 IND filing with drug development and regulatory consulting services, including CMC and pharmaceutical toxicology, plus the clinical development plan and protocols. Frontag...